{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:20:26Z","timestamp":1791390026195,"version":"4.3.3"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82003736"],"award-info":[{"award-number":["82003736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["82474006"],"award-info":[{"award-number":["82474006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00520-026-10549-6","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:42:07Z","timestamp":1773204127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment"],"prefix":"10.1007","volume":"34","author":[{"given":"Hai-yun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-tao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"8","key":"10549_CR1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573\u2013584","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10549_CR2","first-page":"453","volume":"4","author":"F Muggia","year":"2021","unstructured":"Muggia F, Bonetti A (2021) History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications. Cancer Drug Resist 4(2):453\u2013462","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"10549_CR3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/17425255.2019.1622679","volume":"15","author":"P Alberti","year":"2019","unstructured":"Alberti P (2019) Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol 15(6):487\u2013497","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10549_CR4","doi-asserted-by":"crossref","unstructured":"Staff NP et al (2019) Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24 Suppl 2(Suppl 2)S26-s39","DOI":"10.1111\/jns.12335"},{"issue":"3","key":"10549_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.seminoncol.2021.09.004","volume":"48","author":"S Zhang","year":"2021","unstructured":"Zhang S (2021) Chemotherapy-induced peripheral neuropathy and rehabilitation: a review. Semin Oncol 48(3):193\u2013207","journal-title":"Semin Oncol"},{"issue":"6","key":"10549_CR6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba S, Kalayda GV (2016) Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 77(6):1103\u20131124","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10549_CR7","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.21873\/anticanres.14220","volume":"40","author":"O Maeda","year":"2020","unstructured":"Maeda O et al (2020) Pegylated liposomal doxorubicin\/oxaliplatin chemotherapy can overcome cisplatin resistance in spectrin \u03b1II-overexpressing ovarian carcinoma. Anticancer Res 40(5):2497\u20132507","journal-title":"Anticancer Res"},{"issue":"9","key":"10549_CR8","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00415-020-09942-w","volume":"268","author":"L Kang","year":"2021","unstructured":"Kang L et al (2021) Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol 268(9):3269\u20133282","journal-title":"J Neurol"},{"issue":"1","key":"10549_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","volume":"40","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. J Exp Clin Cancer Res 40(1):331","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10549_CR10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40122-017-0092-3","volume":"7","author":"V Brozou","year":"2018","unstructured":"Brozou V, Vadalouca A, Zis P (2018) Pain in platin-induced neuropathies: a systematic review and meta-analysis. Pain Ther 7(1):105\u2013119","journal-title":"Pain Ther"},{"issue":"6","key":"10549_CR11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00280-012-2006-8","volume":"70","author":"M Lucchetta","year":"2012","unstructured":"Lucchetta M et al (2012) Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol 70(6):899\u2013902","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10549_CR12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3988\/jcn.2025.0022","volume":"21","author":"HJ Jung","year":"2025","unstructured":"Jung HJ et al (2025) Oxaliplatin-induced acute peripheral nerve hyperexcitability. J Clin Neurol 21(3):235\u2013237","journal-title":"J Clin Neurol"},{"key":"10549_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107905","volume":"164","author":"P Alberti","year":"2020","unstructured":"Alberti P et al (2020) Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity. Neuropharmacology 164:107905","journal-title":"Neuropharmacology"},{"issue":"Pt 10","key":"10549_CR14","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","volume":"132","author":"SB Park","year":"2009","unstructured":"Park SB et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132(Pt 10):2712\u20132723","journal-title":"Brain"},{"issue":"30","key":"10549_CR15","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33(30):3416\u20133422","journal-title":"J Clin Oncol"},{"issue":"3","key":"10549_CR16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","volume":"157","author":"L Ventzel","year":"2016","unstructured":"Ventzel L et al (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560\u2013568","journal-title":"Pain"},{"issue":"7","key":"10549_CR17","first-page":"1999","volume":"22","author":"AJ Beijers","year":"2014","unstructured":"Beijers AJ, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999\u20132007","journal-title":"Support Care Cancer"},{"issue":"1","key":"10549_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000094376","volume":"56","author":"A Pietrangeli","year":"2006","unstructured":"Pietrangeli A et al (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13\u201316","journal-title":"Eur Neurol"},{"issue":"19","key":"10549_CR19","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/cncr.28234","volume":"119","author":"AA Argyriou","year":"2013","unstructured":"Argyriou AA et al (2013) Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer 119(19):3570\u20133577","journal-title":"Cancer"},{"issue":"1","key":"10549_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","volume":"82","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA et al (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51\u201377","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10549_CR21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","volume":"16","author":"SB Park","year":"2011","unstructured":"Park SB et al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708\u201316","journal-title":"Oncologist"},{"issue":"10","key":"10549_CR22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.0b013e31822cfc59","volume":"77","author":"AZ Burakgazi","year":"2011","unstructured":"Burakgazi AZ et al (2011) Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 77(10):980\u20136","journal-title":"Neurology"},{"key":"10549_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15111311","author":"A Samolis","year":"2025","unstructured":"Samolis A et al (2025) Intraepidermal nerve fiber density as an indicator of neuropathy predisposition: a systematic review with meta-analysis. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics15111311","journal-title":"Diagnostics"},{"issue":"5","key":"10549_CR24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.22.01637","volume":"41","author":"S Lee","year":"2023","unstructured":"Lee S et al (2023) Potential mediators of oxaliplatin-induced peripheral neuropathy from adjuvant therapy in stage III colon cancer: findings from CALGB (Alliance)\/SWOG 80702. J Clin Oncol 41(5):1079\u20131091","journal-title":"J Clin Oncol"},{"issue":"11","key":"10549_CR25","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/annonc\/mdw404","volume":"27","author":"S Lonardi","year":"2016","unstructured":"Lonardi S et al (2016) Phase III trial comparing 3\u20136 months of adjuvant FOLFOX4\/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol 27(11):2074\u20132081","journal-title":"Ann Oncol"},{"issue":"1","key":"10549_CR26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136\u2013147","journal-title":"J Clin Oncol"},{"issue":"16","key":"10549_CR27","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938\u20132947","journal-title":"J Clin Oncol"},{"issue":"11","key":"10549_CR28","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059\u20132069","journal-title":"J Clin Oncol"},{"issue":"23","key":"10549_CR29","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343\u20132351","journal-title":"N Engl J Med"},{"issue":"3","key":"10549_CR30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2013a GERCOR study. J Clin Oncol 24(3):394\u2013400","journal-title":"J Clin Oncol"},{"issue":"16","key":"10549_CR31","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","volume":"25","author":"SR Land","year":"2007","unstructured":"Land SR et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205\u20132211","journal-title":"J Clin Oncol"},{"issue":"9","key":"10549_CR32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435\u20131442","journal-title":"J Clin Oncol"},{"issue":"12","key":"10549_CR33","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):2006\u20132012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10549_CR34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36\u201346","journal-title":"N Engl J Med"},{"issue":"20","key":"10549_CR35","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra CJ et al (2009) Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27(20):3385\u20133390","journal-title":"J Clin Oncol"},{"issue":"23","key":"10549_CR36","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","volume":"27","author":"E Poplin","year":"2009","unstructured":"Poplin E et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(23):3778\u20133785","journal-title":"J Clin Oncol"},{"issue":"1","key":"10549_CR37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/annonc\/mdp272","volume":"21","author":"C Qvortrup","year":"2010","unstructured":"Qvortrup C et al (2010) A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol 21(1):87\u201391","journal-title":"Ann Oncol"},{"issue":"12","key":"10549_CR38","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/annonc\/mds208","volume":"23","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA et al (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23(12):3116\u20133122","journal-title":"Ann Oncol"},{"issue":"3","key":"10549_CR39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T et al (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol 15(3):305\u2013314","journal-title":"Lancet Oncol"},{"issue":"1","key":"10549_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26(1):141\u2013148","journal-title":"Ann Oncol"},{"issue":"3","key":"10549_CR41","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10120-015-0549-1","volume":"19","author":"H Bando","year":"2016","unstructured":"Bando H et al (2016) Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 19(3):919\u2013926","journal-title":"Gastric Cancer"},{"issue":"12","key":"10549_CR42","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/annonc\/mdx021","volume":"28","author":"S Lonardi","year":"2017","unstructured":"Lonardi S et al (2017) Phase III trial comparing 3\u20136 months of adjuvant FOLFOX4\/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol 28(12):3110","journal-title":"Ann Oncol"},{"issue":"5","key":"10549_CR43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jhbp.439","volume":"24","author":"A Ramaswamy","year":"2017","unstructured":"Ramaswamy A et al (2017) Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. J Hepatobiliary Pancreat Sci 24(5):262\u2013267","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"4","key":"10549_CR44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","volume":"19","author":"TJ Iveson","year":"2018","unstructured":"Iveson TJ et al (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol 19(4):562\u2013578","journal-title":"Lancet Oncol"},{"issue":"6","key":"10549_CR45","first-page":"527","volume":"33","author":"X Zhang","year":"2025","unstructured":"Zhang X et al (2025) Clinical efficacy of compression therapy in preventing oxaliplatin-induced peripheral neuropathy: a prospective, randomized controlled study. Support Care Cancer 33(6):527","journal-title":"Support Care Cancer"},{"issue":"4","key":"10549_CR46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1254\/jphs.10012SC","volume":"112","author":"N Egashira","year":"2010","unstructured":"Egashira N et al (2010) Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci 112(4):473\u2013476","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10549_CR47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/jns.12374","volume":"25","author":"AA Argyriou","year":"2020","unstructured":"Argyriou AA et al (2020) Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. J Peripher Nerv Syst 25(2):178\u2013183","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"10549_CR48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027770","volume":"9","author":"N Kerckhove","year":"2019","unstructured":"Kerckhove N et al (2019) Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS supportive care intergroup. BMJ Open 9(6):e027770","journal-title":"BMJ Open"},{"key":"10549_CR49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuropharm.2018.07.026","volume":"140","author":"L Poupon","year":"2018","unstructured":"Poupon L et al (2018) Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology 140:43\u201361","journal-title":"Neuropharmacology"},{"issue":"5","key":"10549_CR50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/emmm.201100134","volume":"3","author":"J Descoeur","year":"2011","unstructured":"Descoeur J et al (2011) Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 3(5):266\u2013278","journal-title":"EMBO Mol Med"},{"issue":"9","key":"10549_CR51","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/emboj.2009.57","volume":"28","author":"J No\u00ebl","year":"2009","unstructured":"No\u00ebl J et al (2009) The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. Embo j 28(9):1308\u20131318","journal-title":"Embo j"},{"issue":"6","key":"10549_CR52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.neuro.2010.07.006","volume":"31","author":"R Sittl","year":"2010","unstructured":"Sittl R et al (2010) Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology 31(6):694\u2013700","journal-title":"Neurotoxicology"},{"issue":"6","key":"10549_CR53","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.neuro.2008.09.005","volume":"29","author":"A Kagiava","year":"2008","unstructured":"Kagiava A et al (2008) The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 29(6):1100\u20136","journal-title":"Neurotoxicology"},{"issue":"1","key":"10549_CR54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-018-3600-1","volume":"82","author":"B Anon","year":"2018","unstructured":"Anon B et al (2018) Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity. Cancer Chemother Pharmacol 82(1):149\u2013157","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10549_CR55","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/jns.12347","volume":"24","author":"AA Argyriou","year":"2019","unstructured":"Argyriou AA et al (2019) Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(4):298\u2013303","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"10549_CR56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jns.12354","volume":"24","author":"AA Argyriou","year":"2019","unstructured":"Argyriou AA et al (2019) Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(4):360\u2013361","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"10549_CR57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jns.12355","volume":"24","author":"A Modoni","year":"2019","unstructured":"Modoni A, Basso M (2019) Oxaliplatin, neurotoxicity, and the search for the lost channel. J Peripher Nerv Syst 24(4):359","journal-title":"J Peripher Nerv Syst"},{"issue":"12","key":"10549_CR58","doi-asserted-by":"crossref","first-page":"8842","DOI":"10.1007\/s12035-018-1029-5","volume":"55","author":"LI Schmitt","year":"2018","unstructured":"Schmitt LI et al (2018) Oxaliplatin modulates the characteristics of voltage-gated calcium channels and action potentials in small dorsal root ganglion neurons of rats. Mol Neurobiol 55(12):8842\u20138855","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10549_CR59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jphs.2016.01.006","volume":"130","author":"K Yamamoto","year":"2016","unstructured":"Yamamoto K et al (2016) Oxaliplatin administration increases expression of the voltage-dependent calcium channel \u03b12\u03b4-1 subunit in the rat spinal cord. J Pharmacol Sci 130(2):117\u201322","journal-title":"J Pharmacol Sci"},{"issue":"46","key":"10549_CR60","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ et al (2006) Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 103(46):17537\u201317542","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10549_CR61","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-6-82","volume":"6","author":"U Anand","year":"2010","unstructured":"Anand U, Otto WR, Anand P (2010) Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. Mol Pain 6:82","journal-title":"Mol Pain"},{"issue":"2","key":"10549_CR62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2009.04.029","volume":"458","author":"P Gauchan","year":"2009","unstructured":"Gauchan P et al (2009) Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 458(2):93\u201395","journal-title":"Neurosci Lett"},{"issue":"2","key":"10549_CR63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/brain\/awac273","volume":"146","author":"A Marcotti","year":"2023","unstructured":"Marcotti A et al (2023) TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy. Brain 146(2):475\u2013491","journal-title":"Brain"},{"key":"10549_CR64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1744-8069-8-7","volume":"8","author":"T Kawashiri","year":"2012","unstructured":"Kawashiri T et al (2012) L type Ca2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain 8:7","journal-title":"Mol Pain"},{"issue":"9","key":"10549_CR65","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1097\/j.pain.0000000000002906","volume":"164","author":"VD Aloi","year":"2023","unstructured":"Aloi VD et al (2023) TRPM3 as a novel target to alleviate acute oxaliplatin-induced peripheral neuropathic pain. Pain 164(9):2060\u20132069","journal-title":"Pain"},{"key":"10549_CR66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainresbull.2020.03.008","volume":"159","author":"X Liu","year":"2020","unstructured":"Liu X et al (2020) HCN2 contributes to oxaliplatin-induced neuropathic pain by inducing spinal long-term potentiation via activation of NMDA receptor-mediated CaMKII signaling. Brain Res Bull 159:61\u201366","journal-title":"Brain Res Bull"},{"key":"10549_CR67","first-page":"174480691877849","volume":"14","author":"X Liu","year":"2018","unstructured":"Liu X et al (2018) HCN2 contributes to oxaliplatin-induced neuropathic pain through activation of the CaMKII\/CREB cascade in spinal neurons. Mol Pain 14:1744806918778490","journal-title":"Mol Pain"},{"issue":"27","key":"10549_CR68","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","volume":"110","author":"JA Sprowl","year":"2013","unstructured":"Sprowl JA et al (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110(27):11199\u201311204","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10549_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710063","author":"E Ballarini","year":"2022","unstructured":"Ballarini E et al (2022) Sodium-calcium exchanger 2: a pivotal role in oxaliplatin induced peripheral neurotoxicity and axonal damage? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231710063","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10549_CR70","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-31095-9","volume":"13","author":"M Dionisi","year":"2023","unstructured":"Dionisi M et al (2023) Inhibition of NHE1 transport activity and gene transcription in DRG neurons in oxaliplatin-induced painful peripheral neurotoxicity. Sci Rep 13(1):3991","journal-title":"Sci Rep"},{"key":"10549_CR71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2014.06.016","volume":"261","author":"L Di Cesare Mannelli","year":"2014","unstructured":"Di Cesare Mannelli L et al (2014) Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol 261:22\u201333","journal-title":"Exp Neurol"},{"issue":"12","key":"10549_CR72","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jpain.2013.08.002","volume":"14","author":"L Di Cesare Mannelli","year":"2013","unstructured":"Di Cesare Mannelli L et al (2013) Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J Pain 14(12):1585\u2013600","journal-title":"J Pain"},{"key":"10549_CR73","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lfs.2015.03.013","volume":"130","author":"ST Kim","year":"2015","unstructured":"Kim ST et al (2015) Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. Life Sci 130:81\u201387","journal-title":"Life Sci"},{"key":"10549_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090324","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim W (2020) The role of satellite glial cells, astrocytes, and microglia in oxaliplatin-induced neuropathic pain. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8090324","journal-title":"Biomedicines"},{"key":"10549_CR75","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2020.103499","volume":"105","author":"LI Schmitt","year":"2020","unstructured":"Schmitt LI et al (2020) Activation and functional modulation of satellite glial cells by oxaliplatin lead to hyperexcitability of sensory neurons in vitro. Mol Cell Neurosci 105:103499","journal-title":"Mol Cell Neurosci"},{"issue":"4","key":"10549_CR76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/j.1532-2149.2012.00219.x","volume":"17","author":"RA Warwick","year":"2013","unstructured":"Warwick RA, Hanani M (2013) The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain 17(4):571\u2013580","journal-title":"Eur J Pain"},{"issue":"21","key":"10549_CR77","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1158\/1078-0432.CCR-18-2152","volume":"25","author":"S Hu","year":"2019","unstructured":"Hu S et al (2019) Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 25(21):6295\u20136301","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10549_CR78","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.2014-0044","volume":"20","author":"A Avan","year":"2015","unstructured":"Avan A et al (2015) Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 20(4):411\u2013432","journal-title":"Oncologist"},{"issue":"2","key":"10549_CR79","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1124\/jpet.116.235283","volume":"359","author":"MR Kelley","year":"2016","unstructured":"Kelley MR et al (2016) Identification and characterization of new chemical entities targeting apurinic\/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther 359(2):300\u2013309","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10549_CR80","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuro.2006.04.010","volume":"27","author":"LE Ta","year":"2006","unstructured":"Ta LE et al (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27(6):992\u20131002","journal-title":"Neurotoxicology"},{"issue":"1","key":"10549_CR81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13046-025-03357-z","volume":"44","author":"X Liu","year":"2025","unstructured":"Liu X et al (2025) USP10\/XAB2\/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. J Exp Clin Cancer Res 44(1):94","journal-title":"J Exp Clin Cancer Res"},{"key":"10549_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112938","author":"C Prieux-Klotz","year":"2022","unstructured":"Prieux-Klotz C et al (2022) A new manganese superoxide dismutase mimetic improves oxaliplatin-induced neuropathy and global tolerance in mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232112938","journal-title":"Int J Mol Sci"},{"key":"10549_CR83","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109828","volume":"245","author":"J Maia","year":"2024","unstructured":"Maia J et al (2024) Mitotherapy prevents peripheral neuropathy induced by oxaliplatin in mice. Neuropharmacology 245:109828","journal-title":"Neuropharmacology"},{"issue":"2","key":"10549_CR84","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2011.08.016","volume":"232","author":"H Zheng","year":"2011","unstructured":"Zheng H, Xiao WH, Bennett GJ (2011) Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 232(2):154\u2013161","journal-title":"Exp Neurol"},{"key":"10549_CR85","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12840","volume":"7","author":"T Miyake","year":"2016","unstructured":"Miyake T et al (2016) Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS. Nat Commun 7:12840","journal-title":"Nat Commun"},{"issue":"4","key":"10549_CR86","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12640-019-00039-5","volume":"36","author":"F Miao","year":"2019","unstructured":"Miao F et al (2019) Engagement of microRNA-155 in exaggerated oxidative stress signal and TRPA1 in the dorsal horn of the spinal cord and neuropathic pain during chemotherapeutic oxaliplatin. Neurotox Res 36(4):712\u2013723","journal-title":"Neurotox Res"},{"issue":"7","key":"10549_CR87","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.pain.2011.02.051","volume":"152","author":"R Nassini","year":"2011","unstructured":"Nassini R et al (2011) Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152(7):1621\u20131631","journal-title":"Pain"},{"issue":"2","key":"10549_CR88","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s12035-016-0364-7","volume":"55","author":"I Bobylev","year":"2018","unstructured":"Bobylev I et al (2018) Depletion of mitofusin-2 causes mitochondrial damage in cisplatin-induced neuropathy. Mol Neurobiol 55(2):1227\u20131235","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10549_CR89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","volume":"238","author":"H Zheng","year":"2012","unstructured":"Zheng H, Xiao WH, Bennett GJ (2012) Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 238(2):225\u2013234","journal-title":"Exp Neurol"},{"issue":"11","key":"10549_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225586","volume":"14","author":"T Maruta","year":"2019","unstructured":"Maruta T et al (2019) Upregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain. PLoS ONE 14(11):e0225586","journal-title":"PLoS ONE"},{"issue":"1","key":"10549_CR91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170814","volume":"12","author":"PG Makker","year":"2017","unstructured":"Makker PG et al (2017) Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One 12(1):e0170814","journal-title":"PLoS One"},{"issue":"10","key":"10549_CR92","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1002\/ijc.32652","volume":"146","author":"H Gu","year":"2020","unstructured":"Gu H et al (2020) High mobility group box-1-toll-like receptor 4-phosphatidylinositol 3-kinase\/protein kinase B-mediated generation of matrix metalloproteinase-9 in the dorsal root ganglion promotes chemotherapy-induced peripheral neuropathy. Int J Cancer 146(10):2810\u20132821","journal-title":"Int J Cancer"},{"issue":"6","key":"10549_CR93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198359","volume":"13","author":"V Stojanovska","year":"2018","unstructured":"Stojanovska V et al (2018) Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLoS ONE 13(6):e0198359","journal-title":"PLoS ONE"},{"issue":"1","key":"10549_CR94","doi-asserted-by":"publisher","first-page":"11729","DOI":"10.1038\/s41598-019-48231-z","volume":"9","author":"L Brandolini","year":"2019","unstructured":"Brandolini L et al (2019) DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain. Sci Rep 9(1):11729","journal-title":"Sci Rep"},{"issue":"6","key":"10549_CR95","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jnci\/djz011","volume":"111","author":"SG Dorsey","year":"2019","unstructured":"Dorsey SG et al (2019) The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Natl Cancer Inst 111(6):531\u2013537","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10549_CR96","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1038\/s41598-017-08891-1","volume":"7","author":"S Yamamoto","year":"2017","unstructured":"Yamamoto S et al (2017) Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Sci Rep 7(1):9661","journal-title":"Sci Rep"},{"issue":"11","key":"10549_CR97","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-24-3964","volume":"31","author":"C Li","year":"2025","unstructured":"Li C et al (2025) Riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer: a phase I clinical trial. Clin Cancer Res 31(11):2115\u20132123","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10549_CR98","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1085\/jgp.20028651","volume":"121","author":"MF Sheets","year":"2003","unstructured":"Sheets MF, Hanck DA (2003) Molecular action of lidocaine on the voltage sensors of sodium channels. J Gen Physiol 121(2):163\u2013175","journal-title":"J Gen Physiol"},{"issue":"1","key":"10549_CR99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tcm.2010.03.002","volume":"20","author":"MF Sheets","year":"2010","unstructured":"Sheets MF et al (2010) Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med 20(1):16\u201321","journal-title":"Trends Cardiovasc Med"},{"issue":"5","key":"10549_CR100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuropharm.2008.06.007","volume":"55","author":"B Ling","year":"2008","unstructured":"Ling B et al (2008) Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology 55(5):724\u20138","journal-title":"Neuropharmacology"},{"issue":"3","key":"10549_CR101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2006.09.016","volume":"128","author":"B Ling","year":"2007","unstructured":"Ling B et al (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128(3):225\u2013234","journal-title":"Pain"},{"key":"10549_CR102","volume":"2017","author":"SAS van den Heuvel","year":"2017","unstructured":"van den Heuvel SAS et al (2017) Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res Manag 2017:8053474","journal-title":"Pain Res Manag"},{"issue":"2","key":"10549_CR103","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neuron.2016.09.026","volume":"92","author":"A Tedeschi","year":"2016","unstructured":"Tedeschi A et al (2016) The calcium channel subunit Alpha2delta2 suppresses axon regeneration in the adult CNS. Neuron 92(2):419\u2013434","journal-title":"Neuron"},{"issue":"7","key":"10549_CR104","first-page":"2927","volume":"30","author":"MW Saif","year":"2010","unstructured":"Saif MW et al (2010) Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 30(7):2927\u20132933","journal-title":"Anticancer Res"},{"issue":"10","key":"10549_CR105","first-page":"1154","volume":"22","author":"DC de Andrade","year":"2017","unstructured":"de Andrade DC et al (2017) Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized. Double-Blind Trial Oncologist 22(10):1154-e105","journal-title":"Double-Blind Trial Oncologist"},{"issue":"4","key":"10549_CR106","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/138161206775474468","volume":"12","author":"K Yamaoka","year":"2006","unstructured":"Yamaoka K, Vogel SM, Seyama I (2006) Na+ channel pharmacology and molecular mechanisms of gating. Curr Pharm Des 12(4):429\u201342","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10549_CR107","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejca.2010.10.006","volume":"47","author":"N Knijn","year":"2011","unstructured":"Knijn N et al (2011) The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47(3):369\u201374","journal-title":"Eur J Cancer"},{"issue":"4","key":"10549_CR108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","volume":"29","author":"A Grothey","year":"2011","unstructured":"Grothey A et al (2011) Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29(4):421\u20137","journal-title":"J Clin Oncol"},{"issue":"10","key":"10549_CR109","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","volume":"32","author":"CL Loprinzi","year":"2014","unstructured":"Loprinzi CL et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol 32(10):997\u20131005","journal-title":"J Clin Oncol"},{"key":"10549_CR110","volume":"13","author":"CH Han","year":"2013","unstructured":"Han CH et al (2013) Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. BMC Cancer 13:495","journal-title":"BMC Cancer"},{"issue":"12","key":"10549_CR111","first-page":"7855","volume":"29","author":"DL Hertz","year":"2021","unstructured":"Hertz DL et al (2021) Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912). Support Care Cancer 29(12):7855\u20137863","journal-title":"Support Care Cancer"},{"issue":"28","key":"10549_CR112","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325\u20133348","journal-title":"J Clin Oncol"},{"key":"10549_CR113","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107417","volume":"205","author":"GA Higgins","year":"2020","unstructured":"Higgins GA, Fletcher PJ, Shanahan WR (2020) Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther 205:107417","journal-title":"Pharmacol Ther"},{"issue":"13","key":"10549_CR114","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u201367","journal-title":"JAMA"},{"key":"10549_CR115","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12421","author":"EM Smith","year":"2017","unstructured":"Smith EM et al (2017) Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB\/alliance 170601. Eur J Cancer Care (Engl). https:\/\/doi.org\/10.1111\/ecc.12421","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"5","key":"10549_CR116","first-page":"2085","volume":"24","author":"T Kus","year":"2016","unstructured":"Kus T et al (2016) Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study. Support Care Cancer 24(5):2085\u20132091","journal-title":"Support Care Cancer"},{"issue":"3","key":"10549_CR117","first-page":"1071","volume":"24","author":"C Zimmerman","year":"2016","unstructured":"Zimmerman C et al (2016) MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 24(3):1071\u20138","journal-title":"Support Care Cancer"},{"issue":"60","key":"10549_CR118","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.18632\/oncotarget.27248","volume":"10","author":"MA Guillaumot","year":"2019","unstructured":"Guillaumot MA et al (2019) Oxaliplatin-induced neuropathy: the preventive effect of a new super-oxide dismutase modulator. Oncotarget 10(60):6418\u20136431","journal-title":"Oncotarget"},{"issue":"1","key":"10549_CR119","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12958-018-0426-y","volume":"16","author":"Y Qin","year":"2018","unstructured":"Qin Y et al (2018) Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol 16(1):106","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"10549_CR120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/0284186X.2017.1398836","volume":"57","author":"B Glimelius","year":"2018","unstructured":"Glimelius B et al (2018) Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx(\u00ae)): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol 57(3):393\u2013402","journal-title":"Acta Oncol"},{"key":"10549_CR121","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac075","author":"P Pfeiffer","year":"2022","unstructured":"Pfeiffer P et al (2022) Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (POLAR-A\/POLAR-M). JNCI Cancer Spectr. https:\/\/doi.org\/10.1093\/jncics\/pkac075","journal-title":"JNCI Cancer Spectr"},{"key":"10549_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac076","author":"C Teng","year":"2022","unstructured":"Teng C, Vardy JL (2022) \u201cPolar-izing\u201d findings from trials of neuroprotection for oxaliplatin neuropathy. JNCI Cancer Spectr. https:\/\/doi.org\/10.1093\/jncics\/pkac076","journal-title":"JNCI Cancer Spectr"},{"key":"10549_CR123","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/srep02005","volume":"3","author":"C Nativi","year":"2013","unstructured":"Nativi C et al (2013) A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci Rep 3:2005","journal-title":"Sci Rep"},{"key":"10549_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050848","author":"C Solana-Manrique","year":"2022","unstructured":"Solana-Manrique C et al (2022) Antioxidant and neuroprotective effects of carnosine: therapeutic implications in neurodegenerative diseases. Antioxidants. https:\/\/doi.org\/10.3390\/antiox11050848","journal-title":"Antioxidants"},{"key":"10549_CR125","volume":"447","author":"X Hu","year":"2023","unstructured":"Hu X et al (2023) Neuroprotective effects of carnosine in a mice stroke model concerning oxidative stress and inflammatory response. J Neurol Sci 447:120608","journal-title":"J Neurol Sci"},{"key":"10549_CR126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2018.12.015","volume":"365","author":"R Yehia","year":"2019","unstructured":"Yehia R et al (2019) L-Carnosine protects against oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a perspective on targeting Nrf-2 and NF-\u03baB pathways. Toxicol Appl Pharmacol 365:41\u201350","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10549_CR127","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10719-023-10141-8","volume":"40","author":"M Fazzari","year":"2023","unstructured":"Fazzari M et al (2023) GM1 structural requirements to mediate neuronal functions. Glycoconj J 40(6):655\u2013668","journal-title":"Glycoconj J"},{"key":"10549_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119558","author":"Z Guo","year":"2023","unstructured":"Guo Z (2023) Ganglioside GM1 and the central nervous system. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119558","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10549_CR129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.biopha.2012.01.002","volume":"66","author":"XF Chen","year":"2012","unstructured":"Chen XF et al (2012) The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study. Biomed Pharmacother 66(4):279\u201384","journal-title":"Biomed Pharmacother"},{"key":"10549_CR130","volume":"11","author":"Y Zhu","year":"2013","unstructured":"Zhu Y et al (2013) Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors. World J Surg Oncol 11:19","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10549_CR131","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cam4.2693","volume":"9","author":"DS Wang","year":"2020","unstructured":"Wang DS et al (2020) Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II\/III colorectal cancer. Cancer Med 9(1):151\u2013159","journal-title":"Cancer Med"},{"issue":"8","key":"10549_CR132","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24598","volume":"36","author":"Y Yokoyama","year":"2022","unstructured":"Yokoyama Y et al (2022) Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-photodiode array detection. J Clin Lab Anal 36(8):e24598","journal-title":"J Clin Lab Anal"},{"issue":"14","key":"10549_CR133","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H et al (2025) Management of chronic myeloid leukemia in 2025. Cancer 131(14):e35953","journal-title":"Cancer"},{"issue":"9","key":"10549_CR134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106485","volume":"9","author":"MR Kelley","year":"2014","unstructured":"Kelley MR et al (2014) Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One 9(9):e106485","journal-title":"PLoS One"},{"issue":"4-5","key":"10549_CR135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/bdd.2226","volume":"41","author":"R Murgasova","year":"2020","unstructured":"Murgasova R et al (2020) Non-clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist. Biopharm Drug Dispos 41(4\u20135):166\u2013183","journal-title":"Biopharm Drug Dispos"},{"key":"10549_CR136","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102415","volume":"73","author":"AJ Shepherd","year":"2023","unstructured":"Shepherd AJ, Rice AS, Smith MT (2023) Angiotensin II type 2 receptor signalling as a pain target: bench, bedside and back-translation. Curr Opin Pharmacol 73:102415","journal-title":"Curr Opin Pharmacol"},{"key":"10549_CR137","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynpai.2020.100048","volume":"8","author":"NW Martinez","year":"2020","unstructured":"Martinez NW et al (2020) Metformin protects from oxaliplatin induced peripheral neuropathy in rats. Neurobiol Pain 8:100048","journal-title":"Neurobiol Pain"},{"issue":"12","key":"10549_CR138","first-page":"5441","volume":"23","author":"YL Zhang","year":"2019","unstructured":"Zhang YL et al (2019) Effects of compound porcine cerebroside and ganglioside on neurotoxicity caused by oxaliplatin chemotherapy: preliminary results. Eur Rev Med Pharmacol Sci 23(12):5441\u20135448","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10549_CR139","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.2147\/DDDT.S385914","volume":"16","author":"M Ali","year":"2022","unstructured":"Ali M, Aziz T (2022) The combination of zinc and melatonin enhanced neuroprotection and attenuated neuropathy in oxaliplatin-induced neurotoxicity. Drug Des Devel Ther 16:3447\u20133463","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10549_CR140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1172\/JCI68730","volume":"124","author":"R Coriat","year":"2014","unstructured":"Coriat R et al (2014) Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest 124(1):262\u201372","journal-title":"J Clin Invest"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10549-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:42:28Z","timestamp":1776235348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10549"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10549-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"302"}}